Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease. Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR. AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo Participants will: * Take study drug or placebo for 12 weeks * Stress Cardiac magnetic resonance imaging * 12 lead electrocardiograms * Complete questionnaires
Sponsor: University of Virginia
You may qualify if…
- ✓ • Female sex.
- ✓ Age ≥18 years.
- ✓ Willing and able to provide written informed consent.
- ✓ Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.
- ✓ No evidence of obstructive epicardial CAD (stenosis \<50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.
- ✓ Diagnosis of CMD defined by CFR \< 2 by CMR
- ✓ Never on SGLT2i
You may not qualify if…
- ✕ History of non-ischemic cardiomyopathy LVEF \<40% or hypertrophic cardiomyopathy.
- ✕ History of congestive heart failure, severe pulmonary disease, liver disease
- ✕ History of acute coronary syndrome (ACS) within previous 30 days
- ✕ Stroke within the last 180 days or intracranial hemorrhage at any time.
- ✕ Severe valvular disease
- ✕ Life expectancy \<3 years, due to non-cardiovascular comorbidity.
- ✕ Pregnancy or women who are breast-feeding
- ✕ Type 1 diabetes mellitus
Where it's recruiting
Charlottesville
Source: ClinicalTrials.gov · NCT06600178 · last updated 2025-10-29